Knights Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR 97403, USA.
Vagelos College of Physicians & Surgeons, Columbia Irving Medical Center, Columbia University, New York, NY 10032, USA.
Int J Mol Sci. 2021 Jan 25;22(3):1170. doi: 10.3390/ijms22031170.
Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD's progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.
新生血管性年龄相关性黄斑变性(渗出性或湿性 AMD)是一种普遍存在的、进行性的视网膜退行性黄斑疾病,其特征是脉络膜新生血管形成,主要影响老年人群,导致视力逐渐下降。年龄、种族、遗传、虹膜颜色、吸烟、饮酒、BMI 和饮食等风险因素都与 nvAMD 的进展有关,抗血管内皮生长因子(anti-VEGF)治疗是该病的主要治疗方法。目前的治疗进展虽然可以减缓疾病的进展,但不能治愈或逆转其病程。基因治疗、Rho-激酶抑制剂和左旋多巴等新疗法为治疗提供了新的潜在靶点。